Clinical Data's PGxHealth Sues Two Chemical Firms for Infringing Cardiac Stress Imaging Drug

PGxHealth has charged Toronto Research Chemicals and Santa Cruz Biotechnology for infringement because they both market the compound apadenoson, the primary ingredient of Stedivaze, a coronary vasodilator that PGxHealth is developing for myocardial perfusion imaging.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.